SeekIn Presents New Data Supporting its Pan-cancer Early Detection Test at the Early Detection of Cancer Conference 2022
- Written by PR Newswire
The large case-control study demonstrates that SeekInCare® has 68.0% sensitivity at 98.0% specificity in 27 different cancer types as a whole.
In both retrospective and prospective studies, the solid performance of SeekInCare® puts it into best-in-class category of multi-cancer early detection (MCED) test.
SHENZHEN, China, Oct. 19, 2022 /PRNe...
